Gain Therapeutics (NASDAQ:GANX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $2.75 target price on the stock. Zacks Investment Research‘s price target indicates a potential upside of 3.77% from the stock’s previous […]